<DOC>
	<DOCNO>NCT01616888</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy use drug elute balloon ( DEB ) paclitaxel treat in-stent restenosis femoropopliteal artery .</brief_summary>
	<brief_title>Paclitaxel Eluting Balloon SFA In-stent Restenosis</brief_title>
	<detailed_description>Peripheral artery disease ( PAD ) low extremity cause claudication , pain legs foot slowly wound affect patient ' quality life increase risk leg amputation death . Both conventional balloon angioplasty ( CBA ) alone CBA plus bare metal stent current primary endovascular therapy treat PAD . However , exaggerate neointimal hyperplasia lead in-stent restenosis associate CBA . Paclitaxel coat balloon recognize safe effective treatment coronary in-stent restenosis , investigator hypothesize applicable femoropopliteal case .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>18 year old chronic symptomatic low limb ischemia define Rutherford categories 2 , 3 , 4 5 instent restenosis occlusion SFA PPA 20mm 200mm participation another investigational drug device trial life expectancy le 12 month acute ischemia and/or acute thrombosis SFA/PPA</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>drug elute balloon paclitaxel</keyword>
	<keyword>stent restenosis</keyword>
	<keyword>femoropopliteal artery</keyword>
	<keyword>angioplasty</keyword>
</DOC>